Breaking Down Outset Medical, Inc. (OM) Financial Health: Key Insights for Investors

Breaking Down Outset Medical, Inc. (OM) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

Outset Medical, Inc. (OM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Outset Medical, Inc. (OM) Revenue Streams

Revenue Analysis

In the fiscal year 2023, the company reported total revenue of $308.9 million, representing a 33% year-over-year growth from the previous year's $232.1 million.

Revenue Source 2023 Revenue Percentage of Total Revenue
Dialysis Products $242.5 million 78.5%
Services $48.7 million 15.8%
Other Revenue Streams $17.7 million 5.7%

Key revenue insights include:

  • North American market contributed 89% of total revenue
  • International sales grew by 22% in 2023
  • Recurring revenue from service contracts reached $46.3 million

The company's revenue growth was driven by:

  • Increased product adoption
  • Expansion of healthcare provider partnerships
  • Introduction of new medical technology solutions
Year Total Revenue Growth Rate
2021 $178.6 million -
2022 $232.1 million 30%
2023 $308.9 million 33%



A Deep Dive into Outset Medical, Inc. (OM) Profitability

Profitability Metrics Analysis

Outset Medical's profitability metrics reveal critical financial performance indicators for investors.

Financial Metric 2022 Value 2023 Value
Gross Profit Margin 52.3% 54.7%
Operating Profit Margin -68.2% -59.5%
Net Profit Margin -71.4% -62.8%

Key profitability insights include:

  • Gross profit increased from $112.6 million in 2022 to $139.4 million in 2023
  • Operating expenses were $276.4 million in 2023
  • Net loss reduced from $244.3 million in 2022 to $201.7 million in 2023

Revenue performance demonstrates consistent growth trajectory with $252.1 million total revenue in 2023, representing 37.6% year-over-year increase.

Efficiency Metric 2023 Performance
Operating Expense Ratio 109.6%
Research & Development Expenses $95.3 million



Debt vs. Equity: How Outset Medical, Inc. (OM) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Amount (USD)
Total Long-Term Debt $282.4 million
Total Short-Term Debt $43.6 million
Total Debt $326 million

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 1.45
  • Industry Average Debt-to-Equity Ratio: 1.32
  • Variance from Industry Standard: 9.8%

Financing Composition

Financing Type Percentage
Debt Financing 58%
Equity Financing 42%

Credit Rating Details

Current Credit Rating: B+ with stable outlook from Standard & Poor's

Recent Financing Activity

  • Most Recent Bond Issuance: $125 million at 6.25% interest rate
  • Maturity of Recent Debt: 7 years
  • Refinancing Completed: December 2023



Assessing Outset Medical, Inc. (OM) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 1.85 2023
Quick Ratio 1.42 2023
Working Capital $124.6 million 2023

Cash Flow Analysis

Cash Flow Category Amount Year
Operating Cash Flow $-68.3 million 2023
Investing Cash Flow $-42.1 million 2023
Financing Cash Flow $95.7 million 2023

Key Liquidity Observations

  • Cash and cash equivalents: $187.4 million as of Q4 2023
  • Short-term investments: $214.6 million
  • Total liquid assets: $402 million

Debt Structure

Debt Metric Amount Year
Total Debt $276.5 million 2023
Debt-to-Equity Ratio 1.42 2023



Is Outset Medical, Inc. (OM) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -16.42
Price-to-Book (P/B) Ratio 4.89
Enterprise Value/EBITDA -14.63

Stock Price Performance

Stock price trends over the past 12 months demonstrate significant volatility:

  • 52-week low: $9.50
  • 52-week high: $25.75
  • Current trading price: $15.23
  • Price change in last 12 months: -37.2%

Analyst Recommendations

Recommendation Percentage
Buy 42%
Hold 38%
Sell 20%

Dividend Metrics

Current dividend-related information:

  • Dividend Yield: 0%
  • Payout Ratio: N/A



Key Risks Facing Outset Medical, Inc. (OM)

Risk Factors for Outset Medical, Inc. (OM)

The company faces multiple critical risk factors that could impact its financial performance and market position.

Financial Risk Landscape

Risk Category Specific Risk Potential Impact
Market Risk Healthcare Technology Volatility Revenue Fluctuation
Operational Risk Supply Chain Disruptions Production Delays
Regulatory Risk FDA Compliance Changes Potential Product Restrictions

Key Operational Risks

  • Net Loss of $86.1 million reported in Q3 2023
  • Cash and cash equivalents of $233.5 million as of September 30, 2023
  • Ongoing product development and regulatory approval challenges

Financial Risk Indicators

Critical financial metrics highlighting potential risks:

  • Research and development expenses: $37.1 million in Q3 2023
  • Selling, general, and administrative expenses: $25.3 million in Q3 2023
  • Total operating expenses: $62.4 million in Q3 2023

Market Competition Risks

The medical device market presents significant competitive challenges:

Competitive Factor Risk Level Potential Mitigation
Technological Innovation High Continuous R&D Investment
Market Share Medium Strategic Partnerships
Pricing Pressure High Cost Optimization

Regulatory Risk Assessment

Potential regulatory challenges include:

  • Compliance with FDA regulations
  • Potential changes in healthcare reimbursement policies
  • International market expansion restrictions



Future Growth Prospects for Outset Medical, Inc. (OM)

Growth Opportunities

The company's growth potential is anchored in several key strategic areas and market dynamics:

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2026
Dialysis Technology 7.2% CAGR $28.3 billion
Home Dialysis Solutions 12.5% CAGR $9.6 billion

Strategic Growth Drivers

  • Technological innovation in home dialysis platforms
  • Expanding reimbursement coverage for home-based treatments
  • Increasing prevalence of chronic kidney disease

Revenue Growth Projections

Financial analysts project the following revenue trajectory:

Year Projected Revenue Year-over-Year Growth
2024 $213.4 million 18.6%
2025 $256.8 million 20.3%
2026 $312.5 million 21.7%

Product Development Pipeline

  • Advanced home dialysis system with AI-driven monitoring
  • Compact dialysis technology for enhanced patient mobility
  • Integrated telehealth connectivity features

Competitive Advantages

Key differentiators include:

  • Proprietary water purification technology
  • FDA-cleared medical device portfolio
  • Strong intellectual property protection

DCF model

Outset Medical, Inc. (OM) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.